HC Wainwright Cuts Bicara Therapeutics (NASDAQ:BCAX) Price Target to $41.00
Bicara Therapeutics (NASDAQ:BCAX – Free Report) had its price objective cut by HC Wainwright from $44.00 to $41.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Bicara Therapeutics’ FY2026 earnings at ($2.59) EPS. Several other research analysts also […]
Bicara Therapeutics (NASDAQ:BCAX – Free Report) had its price objective cut by HC Wainwright from $44.00 to $41.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Bicara Therapeutics’ FY2026 earnings at ($2.59) EPS. Several other research analysts also […]
